Objective: To determine the continuum of HIV care and factors associated with delayed entry and start of cART in Curaçao.
INTRODUCTION
During the last fifteen years, access to combination antiretroviral therapy (cART) has been scaled-up in the Caribbean region, which has resulted in a drop in the number of acquired immunodeficiency syndrome (AIDS)-related deaths from 20,000 in 2005 to 10,000 in 2011.
(1) However, in many Caribbean countries, late presentation continues to be a major obstacle for a successful outcome of cART, in part because of barriers for HIV testing. (2) (3) (4) (5) (6) (7) (8) (9) The continuum of HIV care is a dominant paradigm in engagement in HIV care. (12) , emphasizing the need for data on virological suppression per country against which national cART implementation programs can be assessed.
In this study, we aim to determine the engagement in different stages of the continuum of care for individuals who were newly diagnosed with HIV-1 infection in Curaçao between 2000 and 2010. Besides, we investigate factors associated with delayed entry into care amongst newly diagnosed individuals and factors associated with delayed start of cART after entry.
SUBJECTS AND METHODS
Curaçao is a Caribbean island and part of the former Netherlands Antilles. It has approximately 140,000 inhabitants and the estimated HIV prevalence ranges from 0.61% to 
Statistical analysis
Logistic regression models were used to analyse the impact of gender, age, year of diagnosis, and SAS software (version 9.3; SAS Institute, Cary, North Carolina, USA) were used for data analysis. were using cART and 149 individuals (83% of those on cART) showed viral suppression. Of the 367 individuals who entered into care, 214 (58%) had done so within 3 months after diagnosis. In a multivariate analysis, being diagnosed in the period 2005-2010 and, to a lesser extent, older age at the time of diagnosis were associated with a higher probability of entering care within 3 months (Table 2) . This study includes all newly diagnosed HIV-1-positive individuals in one single country over a period of more than ten years, using exact time frames and thereby providing data for optimizing the effect of cART nationwide. However, our study has several limitations. First, limited additional demographic data were available for newly diagnosed HIV-positive individuals in Curaçao. Clinical data were only available for those patients who succeeded linkage to care, stressing the need to optimize surveillance data and guaranteeing linkage after diagnosis. Second, since the HIV care continuum is more dynamic (with patients being in and out of HIV care before and after starting cART and not a simple linear pathways assumed in our study), we may have overestimated the proportion of patients who achieved viral suppression. Previously we showed high incidence of intermittent care before and after starting cART. Also, during the study period of ten years, different guidelines were used of when to start cART, which may have influenced our results. cART, combination antiretroviral therapy; Viral suppression 6 months after start, HIV-1 RNA measurement < 400 copies/ml; On-cART, using combination antiretroviral therapy. *Proportion of individuals who are diagnosed with HIV-1 infection, who have entered into care and known not to have died or emigrated. 
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